Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. released preliminary figures for its variable investment income for the quarter ended June 30, 2026. The company currently estimates this income will be between $220 million and $270 million (pre-tax), which it contrasts with its full-year 2026 variable investment income guidance of approximately $1.6 billion (pre-tax).
Variable investment income reflects returns from private equity, real estate and other funds, as well as prepayment fees. MetLife emphasizes that these numbers are unaudited, based on information available to management as of the disclosure date, and may differ materially once full closing procedures are complete. The company cautions readers not to rely on these estimates as a substitute for full U.S. GAAP financial statements or to infer performance for future periods.
MetLife (proposed sales reported on Form 144) — Multiple affiliated accounts reported proposed sales of Common Stock via Form 144. The excerpt lists specific proposed sale entries with dates and amounts, including 121 shares for 04/02/2026 ($8,557.12), 144 shares for 05/05/2026 ($11,505.60), and other transactions through 06/18/2026.
The transactions are attributed to named accounts such as Separate Account, Separate Account II, Separate Account SPI, and MetLife 401k Plan Trust-Large Cap Equity Index. The filing lists broker and trade details for earlier sales and indicates cash sales in the past three months. This Form 144 disclosure notifies the market of proposed resale activity by related accounts.
MetLife, Inc. shareholders held their annual meeting on June 16, 2026. Investors elected eleven directors to terms expiring at the 2027 annual meeting, with each nominee receiving a large majority of votes cast. Shareholders also ratified Deloitte & Touche LLP as MetLife’s independent auditor for 2026.
In addition, shareholders approved on an advisory (non-binding) basis the compensation paid to MetLife’s Named Executive Officers, as described in the 2026 proxy statement. Overall, the voting results indicate broad shareholder support for the company’s board, executive pay program, and external auditor.
MetLife submissions list multiple Rule 144 notices for proposed sales of Common Stock by several MetLife-related accounts. The excerpt shows individual sale entries with transaction dates such as 03/20/2026, 04/02/2026, 05/05/2026, and 05/28/2026 and specific share quantities per entry.
MetLife submitted a Form 144 reporting proposed sales of Common Stock by multiple MetLife-related accounts. The filing lists transactions dated 03/20/2026, 04/02/2026, 05/05/2026, 05/28/2026 and shows representative share counts such as 145 shares, 120 shares and 121 shares. The filing is dated 06/18/2026 and references the NYSE.
MetLife Inc director Christian Stephane Mumenthaler received an award of 587 shares of MetLife common stock on June 16, 2026, valued at $87.40 per share. This grant is part of non-management director retainer fees and was elected to be deferred under MetLife’s Deferred Compensation Plan for Non-Management Directors.
Following this compensation-related acquisition, Mumenthaler directly holds 3,452 shares of MetLife common stock credited to his account.
Kennard William E reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director William E. Kennard received a grant of 587 shares of common stock as non-management director compensation. The award was valued at $87.40 per share and increased his direct holdings to 47,410 shares. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. The filing also shows 10 shares of common stock held indirectly through the MetLife Policyholder Trust.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 587 shares of MetLife common stock on June 16, 2026 as a grant or award. These shares represent a portion of his non-management director retainer that is paid in stock and deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, he directly holds 9,498 shares.
MetLife Inc. director Diana McKenzie reported an acquisition of common stock as part of non-management director compensation. She received a grant of 587 shares valued at $87.40 per share, increasing her direct holdings to 25,229 shares after the transaction. A portion of her director retainer is paid in MetLife stock, and she elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, indicating this is a compensation-related, non–open-market transaction.
Hay Laura J reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Laura J. Hay received an award of 587 shares of MetLife common stock as part of non-management director compensation. The shares were valued at $87.40 per share on the grant date. Following this award, Hay directly holds 6,318 shares of MetLife common stock. According to the disclosure, she elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning the grant is part of standard board retainer fees rather than an open-market purchase.